{
    "root": "2f87aaf6-bb8b-da1e-e063-6394a90a308a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "HYDROXYUREA",
    "value": "20250304",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "HYDROXYUREA",
            "code": "X6Q56QN5QC"
        }
    ],
    "indications": "hydroxyurea capsules indicated treatment : resistant chronic myeloid leukemia . locally advanced squamous cell carcinomas head neck ( excluding lip ) combination chemoradiation .",
    "contraindications": "individualize treatment based tumor type , disease state , response treatment , patient risk factors , current practice standards . ( 2.1 ) renal impairment : reduce dose hydroxyurea 50 % patients creatinine clearance less 60 ml/min . ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions": "hydroxyurea capsules , usp supplied 500 mg capsules . cap opaque powder blue body opaque pink . capsules imprinted \u201c 83 \u201d body black ink ndc : 70518-4302-00 packaging : 30 1 blister pack store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep tightly closed . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hydroxyurea capsules contraindicated patients demonstrated previous hypersensitivity hydroxyurea component formulation .",
    "indications_original": "Hydroxyurea capsules are indicated for the treatment of:\n                  \n                     Resistant chronic myeloid leukemia.\n                     Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation.",
    "contraindications_original": "Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards. (2.1) Renal impairment: Reduce the dose of\u00a0hydroxyurea\u00a0by 50% in patients with creatinine clearance less than 60 mL/min. (2.3 , 8.6 , 12.3)",
    "warningsAndPrecautions_original": "Hydroxyurea capsules, USP are supplied as 500 mg capsules.\u00a0The cap is opaque powder blue and the body is opaque pink. The capsules are imprinted with \u201c83\u201d on the body in black ink\n                  \n                  NDC: 70518-4302-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep tightly closed.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hydroxyurea capsules\u00a0are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation."
}